Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
33 participants
INTERVENTIONAL
2012-02-29
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Open-label, Phase I/IIa Study of VAC-3S in HIV-1 Patients Who Showed an Immune Response to VAC-3S During IVVAC-3S/P1
NCT02390466
Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART).
NCT02054286
Phase 1 Safety Study of Two Experimental HIV Vaccines
NCT00479999
Immunogenicity and Safety of 2 Schedules of ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients
NCT00219362
A Safety and Immune Response Study of 2 Experimental HIV Vaccines
NCT02404311
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low dose VAC-3S
VAC-3S
Comparison of different doses of vaccine. Liquid form Volume: 0.5 mL - 2 X 0.5 mL for double-dose arm 3 vaccinations at one month apart
Medium dose VAC-3S
VAC-3S
Comparison of different doses of vaccine. Liquid form Volume: 0.5 mL - 2 X 0.5 mL for double-dose arm 3 vaccinations at one month apart
High dose VAC-3S
VAC-3S
Comparison of different doses of vaccine. Liquid form Volume: 0.5 mL - 2 X 0.5 mL for double-dose arm 3 vaccinations at one month apart
Placebo
Placebo
Comparison with experimental vaccine
Double-dose VAC-3S
VAC-3S
Comparison of different doses of vaccine. Liquid form Volume: 0.5 mL - 2 X 0.5 mL for double-dose arm 3 vaccinations at one month apart
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VAC-3S
Comparison of different doses of vaccine. Liquid form Volume: 0.5 mL - 2 X 0.5 mL for double-dose arm 3 vaccinations at one month apart
Placebo
Comparison with experimental vaccine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age between 18 and 55 years
* ART (AntiRetroviral Therapy) initiation 1 year ago
* Plasma HIV RNA below 50 copies per ml on three sequential occasions including V-1 in the past 12 months
* CD4 T cell count above or equal to 200 cells per mm3,
* Nadir CD4 T cell count above or equal to 100 cells per mm3,
* Contraception in women with child-bearing potential
Exclusion Criteria
* Chronic active liver disease, HIV-Hepatitis Coinfection.
* Immunotherapy in the past year, immunosuppressive treatment within the past month.
* History of auto-immune disease
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
InnaVirVax
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Raphael Ho Tsong Fang, DVM, PHD
Role: STUDY_DIRECTOR
InnaVirVax
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital Pitie Salpetriere
Paris, , France
CIC Cochin Pasteur
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Sponsor's website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IVVAC-3S/P1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.